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B I O C H E M I S T R Y
Complexes of the neurotensin receptor 1 with  
small-molecule ligands reveal structural determinants 
of full, partial, and inverse agonism
Mattia Deluigi1*, Alexander Klipp1*, Christoph Klenk1*, Lisa Merklinger1†, Stefanie A. Eberle1‡, 
Lena Morstein1, Philipp Heine1§, Peer R. E. Mittl1, Patrick Ernst1||, Theodore M. Kamenecka2, 
Yuanjun He2, Santiago Vacca1, Pascal Egloff1#, Annemarie Honegger1, Andreas Plückthun1**
Neurotensin receptor 1 (NTSR1) and related G protein–coupled receptors of the ghrelin family are clinically un-
exploited, and several mechanistic aspects of their activation and inactivation have remained unclear. Enabled by 
a new crystallization design, we present five new structures: apo-state NTSR1 as well as complexes with nonpeptide 
inverse agonists SR48692 and SR142948A, partial agonist RTI-3a, and the novel full agonist SRI-9829, providing 
structural rationales on how ligands modulate NTSR1. The inverse agonists favor a large extracellular opening of 
helices VI and VII, undescribed so far for NTSR1, causing a constriction of the intracellular portion. In contrast, the 
full and partial agonists induce a binding site contraction, and their efficacy correlates with the ability to 
mimic the binding mode of the endogenous agonist neurotensin. Providing evidence of helical and side-chain 
rearrangements modulating receptor activation, our structural and functional data expand the mechanistic 
understanding of NTSR1 and potentially other peptidergic receptors.
INTRODUCTION
The neurotensin receptor 1 (NTSR1) is a peptide-binding G protein– 
coupled receptor (GPCR) belonging to the ghrelin receptor family 
(1, 2), which encompasses several physiologically important receptors, 
yet all clinically unexploited to date (3, 4). NTSR1 exerts its function 
upon activation by the endogenous 13–amino acid peptide agonist 
neurotensin (NTS) and the NTS-related hexapeptide neuromedin 
N. The C-terminal hexapeptide portion of NTS, NTS8–13 (H-Arg8-
Arg9-Pro10-Tyr11-Ile12-Leu13-OH; Fig. 1A), represents the binding 
epitope and contains all determinants for NTSR1 activation (5–7). 
Previously reported structures of NTSR1 (8–12) have elucidated the 
binding mode of NTS8–13 and provided insights into the mechanism 
of receptor activation. However, critically, the lack of structures in 
complex with antagonists or inverse agonists has precluded proper 
characterization of the inactive state, and thus, several mechanistic 
aspects of receptor activation and inactivation have remained un-
clear. Moreover, despite considerable efforts, the detailed structural 
rationales behind the mode of action of nonpeptide agonists and 
inverse agonists have largely remained unknown or hypothetical, as 
so far only the structure in complex with the peptide full agonist 
could be determined.
To elucidate structural determinants of full, partial, and inverse 
agonism, we had to find a way to obtain diffracting crystals of all of 
these states with small-molecule ligands. To accomplish this task, 
we established a new crystallization chaperone design by fusing a 
designed ankyrin repeat protein (DARPin) to NTSR1, thereby ex-
panding the toolchest of fusion proteins that help GPCRs to crystallize. 
This strategy has now allowed us to solve the x-ray structures of 
NTSR1 in the apo state as well as in complex with small-molecule ligands 
(Fig. 1A), ranging from the inverse agonists SR48692 and SR142948A 
to the partial agonist RTI-3a and the novel full agonist SRI-9829, 
and to compare these to the NTSR1 structure bound to NTS8–13.
The chemically related nonpeptide ligands SR48692 (Meclinertant) 
and SR142948A were identified by industry-led efforts over two decades 
ago (13, 14). These compounds competitively antagonize NTS- 
mediated effects, such as tumor promotion in various cancers (15–18). 
Furthermore, they were shown to reduce the level of basal activity 
in constitutively active NTSR1 mutants, revealing inverse agonist 
properties (19, 20). More recently, academic efforts aimed to dis-
cover nonpeptide agonists that are metabolically stable and orally 
available. Replacement of the adamantyl moiety of SR48692 with 
L-Leu resulted in “compound 3a” (21), a partial agonist developed at 
the Research Triangle Institute and thus named RTI-3a herein. 
Exploration of different chemical scaffolds led to the discovery of 
indole-based full agonists (22), and further work on this chemical 
series resulted in the development of SRI-9829, a novel nonpeptide 
full agonist that we disclose in this study (Fig. 1, A and E).
Despite these efforts and the many pathophysiological processes 
in which NTSR1 is involved, no drugs targeting this receptor have 
been clinically approved to date (3, 4). In the central nervous system, 
NTSR1 modulates several neuroendocrine and neurotransmitter 
systems, linking this receptor to psychostimulant addiction, schizo-
phrenia, Parkinson’s disease, and other neurodegenerative diseases 
(23, 24). In the periphery, NTSR1 contributes to the regulation of 
the gastrointestinal and vascular systems (25, 26), implicating this 
receptor in intestinal inflammation (27), obesity and related metabolic 
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disorders (28), and cardiovascular diseases (29, 30). NTS also 
acts as a growth factor on a variety of cells (31), and dysregulated 
NTSR1 signaling enhances proliferation, survival, and metastatic 
spreading of many cancers, correlating with a worse prognosis for 
patients (15–17).
The structures obtained in this study reveal the binding modes 
of ligands with diverse biological effects and the conformational 
changes induced by them. Notably, the inverse agonists adopt a tilt-
ed binding mode, which differs from previously published models 
(11, 32, 33). By widening a hydrophobic subpocket, the inverse 
agonists favor a large opening of the extracellular ends of trans-
membrane helix (TM) 6 and especially TM7, which has remained 
undescribed so far for NTSR1, translating in a closure of the G pro-
tein binding site. In contrast, the full and partial agonists act in the 
opposite direction, inducing a contraction of the binding site via a 










































































































































































































Fig. 1. Ligands induce a contraction or expansion of the orthosteric ligand-binding pocket depending on their pharmacological properties. (A) Chemical struc-
tures of full agonists NTS8–13 and SRI-9829, partial agonist RTI-3a, and inverse agonists SR48692 and SR142948A. (B) Ligand-binding cavity volumes in the structures of 
NTSR1-H4X in complex with the ligands indicated. FA, full agonist; PA, partial agonist; IA, inverse agonist; ECL, extracellular loop. (C) Corresponding cavity of apo-state 
NTSR1-H4X. (D) Quantification of the ligand-binding cavity volumes relative to the apo state. The receptor backbone is depicted in cartoon representation in light gray. 
Ligands are shown as sticks, NTS8–13 is colored yellow, SRI-9829 is colored cyan, RTI-3a is colored purple, SR48692 is colored pink, and SR142948A is colored orange. Oxy-
gen, nitrogen, and chlorine atoms are depicted in red, blue, and green, respectively. The ligand-binding cavity volumes are shown as solid surfaces colored as the respec-
tive ligands and were calculated using the program POVME 2.0 (62). (E) Agonist-induced Gq signaling in cells expressing wild-type rNTSR1. Data were normalized to the 
response of 10 mM NTS8–13 and are shown as means ± SEM from 3 to 11 independent experiments performed in duplicate. EC50 (median effective concentration) values, 
NTS8–13: 2.06 (1.62 to 2.61) nM; SRI-9829: 408.6 (262.9 to 635.1) nM; and RTI-3a: 1815 (789 to 4173) nM. Emax as % of 10 mM NTS8–13, NTS8–13: 95.7 (92.9 to 98.5); SRI-9829: 
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with the ability to mimic the binding mode of the endogenous peptide 
agonist NTS. Last, the helical and side-chain rearrangements ob-
served in the extracellular receptor half, in combination with func-
tional data, provide detailed insights into the transmission of the 
activation trigger to the cytosolic side through a polar network and 
an aromatic cluster beneath the agonist pocket. As several crucial 
residues are conserved in related peptide-binding GPCRs, a better 
comprehension of NTSR1 mechanisms has the potential to improve 
our understanding of several other receptors, as well as how to con-
vert peptide agonists into small-molecule full and inverse agonists. 
Furthermore, the structures presented here and our findings provide 
a solid basis for the optimization of ligands that could be useful in 
the treatment of cancers and neurological and metabolic disorders.
RESULTS
NTSR1 crystallization construct
Successful crystallization of NTSR1 previously relied on stabilized 
rat NTSR1 (rNTSR1) variants and the use of NTS8–13 to further 
enhance stability and reduce conformational flexibility (8–11). 
Attempts to obtain crystals of the apo state or of complexes with 
small-molecule ligands failed, however, probably due to the lack of 
sufficient conformational stabilization and the inability to establish 
crystal contacts. To overcome these obstacles, we took advantage of 
a previously developed and highly stable rNTSR1 mutant, NTSR1- H4 
(table S1) (34, 35). Previous studies with NTSR1-H4 enabled identi-
fication of new ligands that show agonistic or antagonistic properties 
on the wild-type receptor (36, 37). Compared to wild-type rNTSR1, 
NTSR1-H4 displays higher affinity for full agonists but decreased affini-
ty for inverse agonists (fig. S1 and table S2), suggesting conformational 
stabilization. This property is likely a key for successful cocrystalli-
zation of agonistic compounds that show low affinity to the wild-type 
receptor or weak efficacy (partial agonists); however, importantly, 
NTSR1-H4 also retained the ability to undergo agonist-induced and 
inverse agonist–induced conformational changes, as described below.
As none of the initially investigated constructs crystallized, neither 
when fused to commonly used crystallization chaperones (38) nor without 
any fusion, we designed a new fusion construct. We fused the C-terminal 
end of TM7 of NTSR1-H4 to the DARPin D12 crystallization chaperone 
(39–41) via a shared helix (fig. S2). This construct, referred to as NTSR1- 
H4X, readily crystallized in complex with the full agonists NTS8–13 
and SRI-9829, the partial agonist RTI-3a, the inverse agonists SR48692 
and SR142948A, as well as in the apo state (figs. S3, A to F, and S4).
The resolution of the structures ranged from 2.5 to 3.2 Å (table S3), 
and the good quality of the electron density allowed unambiguous 
modeling of the ligands and key receptor residues discussed herein 
(figs. S5 and S6). The presence of the fused DARPin neither perturbed 
ligand affinities (fig. S1 and table S2), nor was there any relevant struc-
tural deviation in the seven transmembrane (7TM) bundle compared 
to the same receptor mutant crystallized without DARPin [Protein 
Data Bank (PDB) ID: 4BWB] (9) (fig. S7). In addition, no relevant 
deviation was observed in the NTS binding site of NTSR1-H4X 
compared to the structure of a minimal mutant with retained signaling 
properties, NTSR1-ELF (PDB ID: 4XEE) (10) (fig. S8, A and B).
Architecture of agonist-induced and inverse agonist–bound 
complexes and of apo structure
Comparison of the apo structure with the agonistic and inverse ag-
onistic ligand complexes revealed notable differences in the volume 
of the orthosteric ligand-binding cavities; while the agonists induced 
a reduction of the accessible volume, the inverse agonists acted in 
the opposite direction, leading to a marked expansion of the ortho-
steric cavity (Fig. 1, B to D).
The contraction of the orthosteric pocket of NTSR1-H4X bound 
to NTS8–13 is comparable to what has been observed in the active- 
state hNTSR1-Gi1 complex (PDB ID: 6OS9) (12) (fig. S8C). The 
complex of NTSR1-H4X with the nonpeptide full agonist SRI-9829 
adopts a highly similar conformation, with the extracellular tip of 
TM7 even slightly more contracted toward the receptor center 
(Fig. 2A and fig. S8D). At the extracellular side, both agonist-bound 
complexes thus resemble the fully active state; however, in the ab-
sence of a G protein, TM6 occludes the G protein–binding cavity 
(fig. S9), reflecting stabilization in a signaling-inactive conforma-
tion at the cytosolic side (42).
The complex with the partial agonist RTI-3a exhibits a similar 
arrangement of the helical bundle as observed with the full agonists 
(Fig. 2B). However, a subtle difference in the position of the extra-
cellular tip of TM7—more distant from the receptor center—and 
rearrangements of key side chains in the orthosteric binding site 
(described below) may suggest why the partial agonist is less effec-
tive than the full agonists in inducing and stabilizing a contracted 
ligand-binding pocket.
This trend is confirmed in the apo-state structure, which appears 
to adopt an intermediate state at the extracellular side according to 
the binding site volume (Fig. 1D). In particular, the extracellular tip 
of TM7 appears to be more distant from the receptor center com-
pared to the NTS8–13 complex (by 2.0 Å) (Fig. 2B) and the SRI-9829 
complex (by 3.7 Å), as measured between corresponding Ca atoms of 
residue 3427.26 (superscripts indicate Ballesteros-Weinstein numbering).
Notably, the complexes of NTSR1-H4X with the inverse agonists 
SR48692 and SR142948A exhibit a wider binding site (Fig. 1, B 
and D), mainly as a consequence of TM6 and TM7 adopting a more 
outward-pointing orientation at the extracellular side compared to 
the NTS8–13 complex (by 3.0 and 4.9 Å, respectively) (Fig. 2C). As a 
structural consequence, TM6 adopts a more closed conformation at 
the intracellular side, completely occluding the G protein–binding 
cavity (fig. S10A). Our data thus corroborate the notion that a less 
contracted binding site is characteristic of the inactive state of class 
A GPCRs (43, 44) and reveal that, in this peptidergic GPCR, TM6 
and especially TM7 provide the main lever arms, which could 
thus apply as well to closely related receptors.
The high-resolution structures we obtained in the active- and 
inactive-like states enabled us to analyze the determinants of NTSR1 
activation and inactivation in great detail. However, we anticipated 
that four mutations of NTSR1-H4X, i.e., E124
2.61D, D1503.33E, F3587.42V, 
and S3627.46A, may limit the extent of this analysis. E1242.61 and 
D1503.33 are part of a polar network below the NTS8–13 binding site 
that has been proposed to link agonist binding to the hydrophobic 
receptor core (10, 11, 45). The latter includes F3587.42, while S3627.46 
is part of the Na+-binding pocket. Therefore, we back-mutated 
(denoted “bm”) these four positions to wild-type residues, generat-
ing NTSR1-H4bmX. Initial crystal hits of NTSR1-H4bmX grew in 
far fewer conditions and to a smaller size than NTSR1-H4X, pre-
sumably reflecting a loss of conformational stability. Nevertheless, 
we were able to solve crystal structures in complex with NTS8–13 and 
SR48692 at 2.6- and 2.7-Å resolution, respectively (figs. S3, G and H, 
S11, and fig. S12 and table S4). Similarly to NTSR1-H4X, the complex of 
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arrangement of the TMs (Fig. 2D) [root mean square deviation for Cα 
atoms (RMSDCa) = 1.0 Å between SR48692-bound NTSR1-H4X and 
NTSR1-H4bmX], whereas the NTS8–13-bound structure once again 
exhibits a fully contracted extracellular portion, emphasizing the ability 
of the agonist, but not of the inverse agonist, to trigger and stabilize 
the contraction of the binding site (by 3.4 Å at TM6 and 6.4 Å at TM7 
toward the central axis, as seen in NTSR1-H4bmX). Crucially, the 
aforementioned conformational changes in the extracellular por-
tion are ligand-induced and do not depend on the crystallization 
method [vapor diffusion or lipidic cubic phase (LCP)], crystal packing, 
or the orientation of the DARPin fusion (fig. S13). Although we do 
not draw conclusions regarding TM1, we observe a more outward- 
pointing arrangement in inverse agonist–bound NTSR1-H4X com-
pared to NTSR1-H4bmX (Fig. 2, C and D) that might, however, be 
related to its intrinsic flexibility and to crystal packing forces.
Binding mode of the nonpeptide agonists
NTS8–13 and the nonpeptide agonists SRI-9829 and RTI-3a largely 
share the same binding site (Fig. 3, A to C) (agonist-receptor 
interactions are listed in tables S5 to S7). The binding modes and 
contacts of the full agonist SRI-9829 and of the partial agonist 
RTI-3a overlap to different extents with those of NTS8–13 (Fig. 3, 
A to C and E and F), suggesting that this may underlie their differ-
ent pharmacological properties.
In the lower part of the binding site, the L-Leu moieties of all 
three agonists form highly similar contacts with the receptor. The 
carboxylate of the L-Leu moiety anchors the ligands to the binding 
site by forming a salt bridge with R3276.54 and a strong hydrogen 
bond with Y1463.29, while the isobutyl chain targets a hydrophobic 
subpocket, establishing extensive van der Waals interactions with 
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Fig. 2. Architecture of rNTSR1 structures with full agonist (FA), partial agonist (PA), inverse agonist (IA), or in the apo state, all viewed from the extracellular 
side. For clarity, the ligands and the DARPin fusion are omitted in these overview structures. (A) Overlay of the highly similar structures of NTSR1-H4X bound to the full 
agonists NTS8–13 and SRI-9829. (B) Movement from apo state to partial to full agonist, as seen in NTSR1-H4X; apo state, RTI-3a (PA), NTS8–13 (FA). (C) Movement from inverse 
to full agonist, as seen in NTSR1-H4X; SR48692 (IA), SR142948A (IA), NTS8–13 (FA). (D) Movement from inverse to full agonist, as seen in the back-mutated NTSR1-H4bmX 
construct; SR48692 (IA), NTS8–13 (FA). The receptor backbone is depicted in cartoon representation and is colored as indicated in the legend. Shifts of the extracellular tips 
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M2044.60, M2084.64, P227ECL2, I2385.39, and F3316.58). The impor-
tance of these contacts is underscored by the observation that L-Leu 
is highly preferred in terms of binding and agonist activity over its 
enantiomer D-Leu as well as many other terminal amino acids 
(21, 22, 46). In all three agonists, the L-Leu moiety is connected with 
an amide group to the rest of the ligand (Fig. 1A), and the corre-
sponding amide oxygen is engaged in a strong hydrogen bond with 
TM7 (Y3477.31).
SRI-9829 and RTI-3a considerably differ in their chemical core 
scaffolds (Fig. 3D). The indole core of SRI-9829 occupies a similar 
space as the backbone and side chain of Ile12 in the NTS8–13 complex 
(Fig. 3E), and it interacts with the numerous surrounding aromatic 
residues (F1282.65, F3316.58, F3447.28, Y3477.31, H3487.32, and Y3517.35) 
(Fig. 3B). In strong contrast, the pyrazole core of RTI-3a occupies a 
substantially different space than Ile12 in the NTS8–13 complex 
(Fig. 3F), and it interacts with fewer aromatic residues (F1282.65, 
F3316.58, Y3477.31, and Y3517.35) (Fig. 3C). In addition, SRI-9829 
and RTI-3a also substantially differ in the contacts mediated by 
their substituents pointing toward the extracellular part of the 
pocket. In SRI-9829, the sulfonyl group points toward T226ECL2, 
and the quinoline ring adopts a virtually ideal position to form aro-
matic stacking with F3447.28 and an edge-to-face aromatic interac-
tion with W339ECL3, complemented by van der Waals contacts with 
V224ECL2 (Fig. 3B). The quinoline ring of SRI-9829 thus fills a similar 
space as between Tyr11 and Pro10 in the NTS8–13 complex (Fig. 3E). 
Overall, the L-shaped binding mode of SRI-9829 is thus remarkably 
similar to that of the C-terminal tetrapeptide Pro10-Tyr11-Ile12-
Leu13 of NTS8–13. In light of the crucial role of this tetrapeptide por-
tion in binding and agonist activity (5,  46,  47), the ability of the 
chemical groups of SRI-9829 to mimic its spatial arrangement and 
interactions is likely reflected in the full agonist properties of SRI-
9829 at NTSR1.
In contrast to SRI-9829, the dimethoxyphenyl and chloroquino-
line substituents of RTI-3a occupy a largely different space than Tyr11 
and Pro10 in the NTS8–13 complex (Fig. 3F). The dimethoxyphenyl 
moiety points toward Tyr11 of the NTS8–13 complex; however, its 
phenyl ring adopts a completely different orientation (Fig. 3, C and F). 
In addition, the chloroquinoline moiety occupies a subpocket that 
is entirely neglected in the NTS8–13 and SRI-9829 complexes. While 
the aromatic ring system interacts with the surrounding residues 
(F1282.65, W339ECL3, F3447.28, Y3477.31, and Y3517.35), the chlorine 






































































































Fig. 3. Agonist-binding pockets of rNTSR1 and superposition of agonist-binding modes. (A to C) Detailed interactions of (A) NTS8–13 (FA), (B) SRI-9829 (FA), and 
(C) RTI-3a (PA) with the receptor, viewed from the extracellular side. FA, full agonist; PA, partial agonist. The receptor backbone is depicted in cartoon representation and 
is colored in light gray. Ligands are shown as sticks; colors are as in Fig. 1. Interacting receptor residues are shown as sticks in pale green. L213 and L234 are mutations 
present in NTSR1-H4 (R and V in wild-type rNTSR1, respectively). An ordered water molecule involved in NTS8–13 binding is shown as a red sphere. H-bonds and salt bridg-
es are depicted by dashed blue lines, cation-p interactions are depicted by dashed magenta lines, and halogen-p interactions are depicted by dashed red lines. The 
DARPin fusion has been omitted for clarity. (D) Chemical structures of SRI-9829 and RTI-3a. The core scaffold of each ligand is highlighted either by a dashed red circle 
(indole group) or by a dashed red rectangle (pyrazole group). (E and F) Comparison of the binding modes of (E) NTS8–13 and SRI-9829 (both FA) and of (F) NTS8–13 (FA) and 
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presence of the L-Leu moiety in RTI-3a fulfills an important prereq-
uisite for NTSR1 agonists (21, 22, 46, 48), the large differences in the 
other parts of the ligand compared to NTS8–13 and their structural 
consequences (see below) probably account for the reduced ability 
of RTI-3a to activate NTSR1.
The inverse agonists hinder contraction of the  
extracellular portion
In contrast to the agonists, the inverse agonists SR48692 and 
SR142948A are located in a wider binding pocket (Figs. 1B and 
4, A to C, and fig. S14) and occupy mostly a different space than 
NTS8–13 (Fig. 4, D and E); however, they share the same binding site 
as the peptide agonist. This is consistent with the previously reported 
finding that SR142948A binds entirely in the same site as NTS8–13, 
as evidenced by chemical cross-linking experiments (20). Further-
more, their binding mode is in agreement with site-directed muta-
genesis studies (note S1) and molecular dynamics simulations (20). 
The carboxylate group of both inverse agonists anchors to R3276.54, 
similarly to the agonists; however, it hydrogen-bonds to Y3517.35 
instead of Y1463.29. Consistent with its nonpolar nature, the adamantyl 
moiety of both inverse agonists targets the same hydrophobic sub-
pocket as the L-Leu side chain of the agonists, forming contacts with 
residues of TM3 to TM6 and ECL2 (tables S10 and S11). Notably, 
the sole replacement of the adamantyl moiety of SR48692 with an L-Leu 
side chain converts this inverse agonist into the partial agonist 
RTI-3a (21), raising the question of which mechanisms underlie 
ligand- mediated receptor activation and inactivation.
On the basis of our crystal structures, it appears that inverse 
agonism is related to a steric effect exerted by the bulky adamantyl 
moiety. In contrast to the isobutyl chain of L-Leu, the adamantyl 
moiety favors a substantial widening of the hydrophobic subpocket 
at F3316.58 (Fig. 5 and fig. S15), thereby hindering the contraction of 
the extracellular receptor portion, which is observed for the agonists. 
Conversely, the shape of the isobutyl chain appears to be optimally 
tailored to induce and stabilize a contracted arrangement of TM6 at 
its extracellular tip. Following the widening of the hydrophobic 
subpocket favored by the adamantyl moiety, the remaining chemi-
cal groups of both inverse agonists adopt a similar binding mode 
(Fig. 4F), substantially further away from the receptor center than 
NTS8–13 (Fig. 4, D and E). As a consequence and in strong contrast 
to the agonists, the interactions with activation-crucial residues in 















































Fig. 4. Inverse agonist–binding pockets of rNTSR1 and superposition of binding modes. (A and B) Detailed interactions of (A) NTSR1-H4bmX bound to SR48692 (IA) 
and (B) NTSR1-H4X bound to SR142948A (IA), viewed from the extracellular side. The receptor backbone is depicted in cartoon representation and is colored in light gray. 
Ligands are shown as sticks, SR48692 is colored brown, and SR142948A is colored orange. Interacting receptor residues are shown as sticks in pale green. L234 is a muta-
tion present in NTSR1-H4 and NTSR1-H4bm (V in wild-type rNTSR1). H-bonds and salt bridges are depicted by dashed blue lines and halogen-p interactions by dashed red 
lines. The DARPin fusion has been omitted for clarity. In the SR142948A complex, the side chains of F331 and Y347, which may form hydrophobic contacts with the ligand, 
were not well resolved by their electron density and were therefore not modeled. The alkylamine chain of the latter ligand is likely directed toward the extracellular space 
but is not visible in the electron density, probably due to its conformational flexibility (fig. S5E) (20). (C) Chemical structures of SR48692 and SR142948A. The pyrazole core 
scaffold of each ligand is highlighted by a dashed red rectangle. (D to F) Comparison of the binding modes of (D) NTS8–13 (FA) and SR48692 (IA), (E) NTS8–13 (FA) and 
SR142948A (IA), and (F) SR48692 (IA) and SR142948A (IA), viewed from a similar perspective as in (A) and (B). FA, full agonist; IA, inverse agonist. NTS8–13 is depicted in 
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no contacts tethering to the ECL2 b hairpin at the opposite side of 
the extracellular portion (Fig. 4, A and B). Overall, these differences 
and their structural consequences probably explain the inability of 
SR48692 and SR142948A to activate NTSR1 and provide a rationale 
of how they may stabilize the inactive state.
ECL3 and TM7 interactions are crucial for agonist-induced 
NTSR1 activation
Although the presence of an L-Leu moiety is highly beneficial for 
agonist potency and efficacy (21, 22, 48), its presence is not suffi-
cient to guarantee receptor activation (neither full nor partial), and 
the question thus arises of how other functional groups in agonist 
ligands modulate receptor activation. The structures obtained in 
this study now allow us to broadly address this question.
All three agonists bind near the receptor center (Fig. 3, A to C). 
Where they extend toward the extracellular space, they form con-
tacts on one wall of the binding site with TM6, ECL3, and TM7, 
while at the opposite wall they are tethered to the ECL2 b hairpin 
and TM2, indicating that this anchoring pattern may be important 
for inducing the contraction of the extracellular receptor portion. 
While the role of the L-Leu moiety in receptor activation appears to 
be largely related to TM6 (discussed above), the other functional 
groups in agonistic ligands appear to modulate receptor activation 
via rearrangements of ECL3 and the extracellular tip of TM7 
(Fig. 6, A to D). Site-directed mutagenesis studies identified a set of 
aromatic rNTSR1 residues belonging to these regions as important 
mediators of agonist potency [(49); Fig. 6E]. Mutagenesis of W339ECL3, 
F3447.28, Y3477.31, H3487.32, and Y3497.33 to Ala, or Phe in the case of 
Y3477.31, caused a moderate drop in NTS8–13 affinity; however, it 
also led to a substantially stronger reduction in potency at the Gq 
pathway [(49); Fig. 6E] and Gs pathway (49) (~100- and 1000-fold, 
respectively). Furthermore, it has been observed that these muta-
tions shift the conformational equilibrium of the receptor toward a 
low-affinity agonist-binding state (49). Together, these findings 
suggest that the aforementioned residues not only are involved in 
agonist binding but also are essential for stabilization of a contract-
ed binding site as required for high-potency G protein activation.
NTS8–13 interacts with W339
ECL3 and other residues in ECL3, and 
with F3447.28, Y3477.31, and H3487.32 in TM7 (Fig. 3A and table S5), 
stabilizing their arrangement toward the receptor center. In contrast, 
weak or no electron density is observed for W339ECL3, F3447.28, and 
H3487.32 in the apo structure (fig. S6F), indicating higher flexibility 
within these regions due to the lack of stabilizing interactions that 
are seen in the NTS8–13 complex. Furthermore, in the NTS8–13 com-
plex, the side chain of H3487.32 is oriented toward the receptor core, 
accompanied by an inward rotation of Y3497.33 and an inward 
movement of the extracellular tip of TM7 (Fig. 6A). In analogy to 
NTS8–13, the full agonist SRI-9829 also interacts with W339ECL3, 
F3447.28, Y3477.31, and H3487.32 (Fig. 3B and table S6), leading to a 
marked inward movement of ECL3 and the extracellular tip of TM7 
(Fig. 6B). Of note, while NTS8–13 establishes several polar interac-
tions with these regions, SRI-9829 largely relies on van der Waals 
and aromatic contacts, with the indole and quinoline rings repre-
senting excellent hydrophobic platforms.
In strong contrast to the full agonists, the partial agonist RTI-3a 
forms fewer and weaker interactions with W339ECL3 and F3447.28 
(Fig. 3C and table S7). Furthermore, the chloroquinoline ring par-
tially covers the space occupied by the H3487.32 side chain in the 
NTS8–13 and SRI-9829 complexes, apparently hindering the inward 
rotation of H3487.32 (Fig. 6C), with the location of the extracellular 
tip of TM7 being reminiscent of the apo structure. Structure-activity 
studies indicated that the chlorine substituent is essential for the 
agonistic properties of this ligand (21), which could be related to the 
halogen-p contacts formed with H3487.32, nonetheless tethering this 
ligand to the tip of TM7.
The extent by which agonist binding can alter the orientation of 
the aforementioned residues is highlighted by comparison of the 
NTS8–13 complex with the structure bound to the inverse agonist 
SR48692. In the latter structure, the side chains of F3447.28, Y3477.31, 
and H3487.32 are considerably further away from the receptor center 
than in the NTS8–13 complex (by 6.2, 8.9, and 5.7 Å, respectively, as 
measured between ring centers) (Fig. 6D), and while weak or no 
electron density is observed for the side chains of W339ECL3 and 
Y3497.33 (fig. S12A), their backbone is more distant as well (by 6.7 and 
3.5 Å, respectively). Furthermore, in the SR48692 complex, this 
cluster of aromatic residues is too distant or flexible to form a stable 
network of aromatic interactions, whereas such a network is estab-
lished in the complexes with the full agonists (Fig. 6, A and B) and 
thus possibly contributes to stabilization of a contracted arrange-
ment of the binding site. In the complex with the partial agonist, 
this network is partially severed by the outward orientation of 

















Fig. 5. Steric effects of the isobutyl and adamantyl groups of agonists and inverse agonists, respectively. (A to C) Superposition of the NTS8–13 (FA) and SR48692 
(IA) complexes solved in this study, showing (A) the tilting of TM6 at F3316.58 and (B) highlighting the space occupied by the isobutyl chain of Leu13 and by F331
6.58 as well 
as (C) the space occupied by the adamantyl moiety and by F3316.58, viewed from the membrane plane. FA, full agonist; IA, inverse agonist. The receptor backbone is de-
picted in cartoon representation. The NTS8–13 complex is colored in yellow, and the SR48692 complex is colored in brown. Side chains are shown as sticks and are colored 
as the corresponding backbone. The isobutyl chain of Leu13 and the adamantyl moiety of SR48692 are shown as sticks and as van der Waals spheres, while the rest of the 
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due to increased flexibility within these regions (Fig. 6A and fig. S6F). 
Overall, the interactions mediated by agonist ligands with ECL3 
and TM7, as well as the resulting structural changes presented here, 
are likely crucial determinants of ligand-induced NTSR1 activation, 
in agreement with functional studies.
Interhelical polar network and hydrophobic core in  
NTSR1 activation
Having established structural details of how agonists cause a contrac-
tion of the extracellular portion of NTSR1 and how inverse agonists 
act in the opposite direction and prevent it, the question arises of 
how these structural rearrangements are transmitted to the intracel-
lular receptor portion. A network of polar interactions beneath the 
NTS8–13 binding site has previously been proposed to link agonist 
binding with the hydrophobic receptor core (10, 11, 45). We there-
fore compared inverse agonist–bound NTSR1-H4bmX with agonist- 
bound NTSR1-ELF (10), a minimal mutant with retained signaling 
properties. This comparison suggests that receptor activation may 
be favored by rotation of the D1503.33 side chain toward the central 





































































































































































Fig. 6. Backbone and side-chain perturbations in the extracellular rNTSR1 portion induced by ligand binding. (A and B) Superposition of the apo structure with the 
complexes of (A) NTS8–13 (FA) and (B) SRI-9829 (FA), viewed from the extracellular side. (C) Superposition of the SRI-9829 (FA) and RTI-3a (PA) complexes. (D) Superpo-
sition of the NTS8–13 (FA) and SR48692 (IA) complexes. FA, full agonist; PA, partial agonist; IA, inverse agonist. Backbone and key residues are shown as cartoon and sticks, 
respectively, and are colored as indicated in the legend. In the apo structure and SR48692 complex, W339 is poorly visible in the electron density (figs. S6F and S12A) and 
is thus shown as transparent thin sticks. Cb indicates that the side chain is not visible in the electron density. Backbone rearrangements between 1 and 3 Å are indicated 
by thin black arrows, and backbone rearrangements >3 Å are indicated by thick black arrows. The ligands, the receptor N terminus, and the DARPin have been omitted 
for clarity. (E) Differences in NTS8–13 affinity (pKi) or potency at Gq signaling (pEC50) for selected mutants relative to wild-type rNTSR1. pKi values were derived from com-
petition ligand-binding experiments (table S8), and pEC50 values were derived from concentration-response curves (table S9). Data are shown as means ± SEM from 
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with the rotation of the guanidinium head group of R3286.55 toward 
the agonist’s carboxylate, as captured in the structure of NTSR1-
ELF (10). The rearrangement of the latter side chain may underlie 
the highly beneficial effect of a carboxylate group for ligand ago-
nism (22), in addition to the anchoring function exerted through a 
salt bridge with R3276.54 (Fig. 3, A to C). Furthermore, the carbox-
ylate group of the agonist appears to adopt a position closer to the 
central axis of the receptor compared to the homologous functional 
group of the inverse agonist (Fig. 7B). This positional difference 
might affect the rearrangements within the polar network and thus 
partially underlie the opposite biological functions of these carboxylate- 
carrying ligands. In the agonist-bound structure, R3276.54 interacts 
with N3557.39, which is, in turn, linked to E1242.61. In the inverse 
agonist–bound structure, we observed a substantial repositioning of 
N3557.39 (Fig. 7A), which appears to weaken the TM2-TM7 linkage.
To confirm our structural observations, we generated single mutants 
of D1503.33, R3286.55, and N3557.39 in wild-type rNTSR1 and probed 
the effect on agonist binding and Gq-mediated signaling (Fig. 7C). 
D1503.33A, R3286.55M, and N3557.39A only slightly affect NTS8–13 
affinity; however, they result in a marked drop in agonist potency. 
This validates the hypothesis that the charges of D1503.33 and R3286.55, 
as well as the N3557.39 side chain, are important for agonist-induced 
receptor activation. Y3517.35 also takes part in the polar network via 
its hydroxyl group; however, this residue appears to exert its function 
mainly through its phenyl ring. This is evidenced by the retained 
NTS8–13 affinity and potency upon mutation to Phe, but not to Ala 
(Fig. 7C), and could reflect an important role in the stabilization of 
R3276.54 through cation-p interactions.
R1493.32 is linked to TM2 via a salt bridge with E1242.61 and to 
TM7 via a cation-p interaction with F3587.42. In a recent nuclear 
magnetic resonance (NMR) study on NTSR1-H4, it was shown that 
the mutation E1242.61D, which weakens the interaction with R1493.32, 
stabilizes the active state of the receptor (50). In agreement, the 
mutations R1493.32M and F3587.42A result in increased affinity for 
NTS8–13 (Fig. 7C), indicating that these mutations likely shift the 
equilibrium toward active conformations, although only F3587.42A 
also results in detectable constitutive activity (fig. S16) (19). Com-
parison of the active- and inactive-like structures does not reveal 
large rearrangements of R1493.32 and F3587.42 (Fig. 7, A and B); 
nonetheless, it is possible that transient weakening of these TM2-
TM3 and TM3-TM7 contacts favors receptor activation. This could 
underlie, at least partially, the upward shift of TM3 corresponding 
to an active state at the intracellular side (1.5 Å at A1573.40 of the 




























































































































































Fig. 7. Interhelical polar network and hydrophobic core residues. (A) Superposition of the interhelical polar network in agonist-bound NTSR1-ELF (PDB ID: 4XEE) (10) 
and inverse agonist–bound NTSR1-H4bmX. FA, full agonist; IA, inverse agonist. TM4, ECL2, part of TM5, and fusion proteins have been omitted. (B) Hydrophobic core 
residues of the same structures as in (A). ECL1, TM3 to TM5, and fusion proteins have been omitted. Receptor residues are shown as sticks, and the ligands are shown as 
thin sticks. Backbone, residues, and ligands are colored as indicated in the legend. Relevant side-chain rearrangements are indicated by black curved arrows, whereas 
backbone rearrangements are indicated by black straight arrows. (C) Effect of single residues on agonist binding and receptor activation. Bars represent differences in 
calculated affinity (pKi) or potency at Gq signaling (pEC50) for each mutant relative to wild-type rNTSR1. pKi values for NTS8–13 were derived from competition ligand- 
binding experiments (table S8); pEC50 values for NTS8–13- induced IP1 generation were derived from concentration-response curves (table S9). Data are shown as 
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thus sense the agonist’s carboxylate and reorient its head group, 
weakening the interaction with E1242.61.
F3587.42 is positioned between Y3246.51 and W3216.48 in a “hydro-
phobic cascade” (10), ending at F3176.44 of the transmission switch 
motif (Fig. 7B). W6.48 and F6.44 are regarded as crucial residues in class 
A GPCRs for the transmission of the agonist-induced activation 
trigger to the G protein–binding interface (51, 52). In other class A 
GPCRs, the role of W6.48 is related to the Na+-binding pocket and 
the associated H-bond network (53, 54). However, the role of W3216.48 
in NTSR1 cannot be fully ascertained because of the absence of a 
functional Na+ pocket in the structures solved in this study. Never-
theless, we observe that the large shift of TM6 upon activation and 
the rotation of F3176.44 are not associated to large rearrangements 
of W3216.48, although a slight tilting of the indole side chain of 
W3216.48 is observed in the inverse agonist–bound structure (Fig. 7B). 
This is interesting, as the relative orientation of W3216.48 to the 
membrane plane has previously been suggested to play a role in 
NTSR1 activation (10, 11). The tilting observed in the inverse agonist– 
bound structure could, in turn, be related to a slight upward shift of 
F3587.42 and Y3246.51. The latter residue may thus link the polar 
network with the hydrophobic cascade, and our functional data in-
dicate that it exerts its function mainly through its phenyl ring 
(Fig. 7C), which could suggest the involvement of cation-p interac-
tions with R3286.55. Unexpectedly, the mutation W3216.48A does 
not substantially affect agonist-induced signaling (Fig. 7C) (11) or 
basal activity (fig. S16); however, it does lead to a substantial  in-
crease in NTS8–13 affinity (Fig. 7C), which nonetheless supports the 
implication of W3216.48 in the modulation of NTSR1 conforma-
tional equilibrium (10, 11). Together, our structural and functional 
data thus suggest that, for receptor activation, a number of rather 
subtle conformational rearrangements are required beneath the 
binding pocket, most likely involving water molecules, and that 
subtle movements in the hydrophobic core critically modulate the 
network of interhelical interactions. Understanding the exact role 
played by water molecules will need further studies, as the resolu-
tion of the inverse agonist–bound inactive structures solved in this 
study does not allow to assess changes in the position of structured wa-
ter molecules compared to the agonist-bound state.
DISCUSSION
NTSR1 recognizes the endogenous peptides NTS and neuromedin 
N. In light of the receptor’s physiological relevance, a number of 
synthetic compounds with diverse biological effects have been de-
veloped; however, their exact binding modes and structural ratio-
nales of action have remained unclear, which precluded a more 
comprehensive understanding of the receptor activation and inacti-
vation mechanisms. To elucidate the detailed structural determi-
nants of agonism and inverse agonism at a peptidergic GPCR and to 
unravel the binding modes of synthetic NTSR1 lead compounds, we 
thus embarked in a major crystallographic effort and solved struc-
tures of rNTSR1 bound to full, partial, and inverse agonists, as well 
as in the apo state.
To achieve this, the new crystallization design exploiting the 
fusion to the DARPin D12 chaperone (39–41) was crucial to make 
this study possible: The DARPin provided strong crystal contacts, 
while the shared helix design (39) proved to be an ideal compromise 
between rigidity and malleability, adapting to different crystal packings. 
This design has thus the potential to enable structure determina-
tion of other challenging targets that have so far resisted to crystal-
lization, perhaps also in complex with several ligands of various 
efficacies. As for traditional intracellular loop 3 (ICL3) fusions, po-
tential structural effects related to a rigidly fused DARPin crystalli-
zation chaperone will require a careful assessment on a case-by-case 
basis in future studies, in particular at the intracellular side and 
proximal to the fusion site on TM7. In our study, fusion of DARPin 
D12 to TM7 via the reported shared helix design did not cause any 
relevant structural deviation in the 7TM bundle of NTS8–13-bound 
NTSR1-H4 compared to the structure obtained without fusion (PDB 
ID: 4BWB) (9), nor did it affect the binding pocket or ligand affini-
ties. Furthermore, our crystallized complexes, bound to the same 
ligands but exhibiting different crystal packings and DARPin orien-
tations, reveal that, although deviations proximal to the fusion 
site can occur, the conformations adopted by the receptor and the 
ligand-binding modes are identical or highly similar. Altogether, 
these findings validate this approach as a valuable tool for GPCR 
crystallography.
All structures presented in this study, including the agonist com-
plexes, adopt a closed helical arrangement at the cytosolic side. This 
is a common outcome in the absence of a G protein, or a mimic 
thereof, which would stabilize a more open conformation. In addi-
tion, it has previously been proposed that a mutation present in 
NTSR1-H4, namely, R1673.50L, may favor a closed conformation at 
the cytosolic side through a “hydrophobic lock” mechanism (9), 
and we found this mutation to be crucial for crystallization of the 
complexes presented in this study. The gain of knowledge for the 
agonist complexes is thus mostly concentrated to the extracellular 
portion, as the structures were obtained without a G protein. The 
inverse agonist complexes exhibit nonetheless a further closure at 
the cytosolic side, in particular of TM6. Thus, to gain insights into 
the mechanism of signal transmission from the binding site to the 
cytosolic side, we reverted four interfering mutations (generating 
NTSR1-H4bmX) and compared the inverse agonist–bound inactive 
conformation (of NTSR1-H4bmX) to previously published structures 
captured in the active or active-like state at the cytosolic side. Struc-
tural observations were subsequently evaluated in binding and func-
tional assays in the context of wild-type rNTSR1.
The extracellular portion of our crystallized constructs appears 
to be conformationally more flexible, as we observed helical and 
side-chain rearrangements in the different ligand complexes and in 
the apo structure. At the extracellular side, the latter exhibits an 
intermediate conformation between the agonist complexes and the 
inverse agonist ones, yet it is more similar to the agonist-bound state, 
which might appear surprising. However, it should be considered 
that most GPCRs naturally sample different conformations in their 
apo form, and it is not straightforward to predict which one will 
correspond to an energy minimum in the well-diffracting crystals. 
Furthermore, it is possible that the presence of stabilizing mutations 
has contributed to shifting the equilibrium toward active-like con-
formations at the extracellular side, as suggested by the increased 
affinity for full agonists.
Nonetheless, in the inverse agonist–bound state, the structures solved 
in this study reveal a pronounced outward tilting of the extracellular ends 
of TM6, and especially TM7, and of ECL3. The inverse agonists largely 
share the same binding site as the agonists; however, they adopt a notably 
tilted binding mode, pointing toward (and almost partially intercalating 
between) TM6 and TM7. This corroborates the observation that 
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modes (55), i.e., ligands can occupy a diverse space within the transmem-
brane bundle or extracellular vestibule. The bulky adamantyl moiety of 
the NTSR1 inverse agonists appears to play a crucial role in the opening 
of the extracellular receptor portion, which translates to a closure of the 
helical bundle at the intracellular side.
Of note, it remains a possibility that a ligand could bind and 
stabilize multiple receptor conformations besides the one captured 
crystallographically, as GPCRs are known to adopt various confor-
mations within the different states (inactive, intermediate, and 
active) they sample. A future area of research should thus focus on 
this aspect; however, this may require the use of experimental and 
computational methods more suitable than crystallography to as-
sess the dynamics of NTSR1 conformational equilibria.
The inactive state of wild-type NTSR1 is likely stabilized by Na+ 
ions, as observed for several other GPCRs (53). Unfortunately, no 
NTSR1 structure to date captured a functional Na+-binding pocket, 
which therefore needs to be addressed by future studies. Neverthe-
less, together, the structures solved in this study shed additional light 
on the polar network beneath the agonist-binding site and on the 
hydrophobic core residues that are involved in the transmission of 
the activation trigger to the intracellular side. Moreover, on the basis 
of the sequence conservation of many crucial residues discussed above, 
such as F6.44, W6.48, Y/F6.51, R6.55, F/Y6.58, and F7.42, it is likely that 
several other members of the ghrelin family share similar principles 
by which the activation trigger is transmitted within the hydrophobic 
core to elicit large-scale helical rearrangements. Our structural 
insights have thus the potential to improve the understanding of 
other physiologically important peptide-binding receptors.
As for NTSR1, none of the ghrelin family receptors has been clini-
cally exploited to date (3, 4). However, after a lag phase of almost two 
decades, it appears that ligands targeting these receptors are close to 
provide proven therapeutic benefits (56–58). For example, recently, the 
radiopharmaceutical 177Lu-3BP-227 (57) based on the NTSR1 ligand 
SR142948A showed promise for treatment of ductal pancreatic adeno-
carcinoma (58), one of the cancers with the highest mortality rates, and 
is expected to be evaluated in clinical trials to treat solid tumors.
Our structural findings also expand the understanding of how 
agonists induce a contraction of the binding site, which has broad 
implications. Noteworthy, the development of the novel nonpeptide 
full agonist SRI-9829 was key to elucidate structural determinants 
of NTSR1 activation, as it allowed us to compare receptor interac-
tions with the chemically divergent full agonist NTS8–13. The complex 
with SRI-9829 reveals that this nonpeptidic full agonist based on an 
indole core occupies a similar space in the pocket as the C-terminal 
tetrapeptide of NTS8–13 and mimics its contacts, leading to a similar 
contraction of the binding site as induced by NTS8–13. However, the 
lack of a moiety forming additional interactions, as Arg8 and Arg9 
do in NTS8–13, probably explains the lower affinity and potency 
compared to the hexapeptide at wild-type rNTSR1, suggesting a 
possible direction for the design of highly potent small-molecule 
full agonists. In contrast to the full agonists, the complex with the 
partial agonist RTI-3a exhibits a slightly less contracted binding site, 
in particular at TM7, which probably translates into a less favored 
opening of the cytosolic side for interactions with the G protein, 
explaining its reduced efficacy.
Overall, it appears that potent NTSR1 full agonists require contacts 
reaching up to the extracellular tip of TM7 and ECL3. In this regard, the 
subtle difference between rat and human NTSR1 at position F/Y7.28 at 
the extracellular tip of TM7 needs to be carefully considered for ligand 
design. Ligand-mediated interactions with TM7 may also be of particu-
lar relevance in light of the known role of TM7 in biased signaling (59).
In conclusion, this study presents the first structures of NTSR1 
bound to small-molecule ligands, ranging from inverse to full ago-
nists, as well as of the apo state, made possible by a new crystalliza-
tion design. Thereby, we elucidated structural determinants of full, 
partial, and inverse agonism at a peptidergic receptor, deepening our 
mechanistic understanding of GPCRs and providing new templates 
for structure- based drug screening and design.
MATERIALS AND METHODS
Synthesis of SRI-9829
A step-by-step synthesis procedure of SRI-9829, as well as the 
corresponding NMR and mass spectrometry characterizations are 
reported in Supplementary Materials and Methods.
Generation of NTSR1-H4X and NTSR1-H4bmX constructs
The rNTSR1 mutant NTSR1-H4 had been obtained previously by 
directed evolution (table S1) (34). NTSR1-H4X was obtained by intro-
ducing the following modifications: deletion of N-terminal residues 
M1–A49 and ICL3 residues E273–T290, and fusion of DARPin D12 
(39–41) to residue L3717.55 via the linker sequence AEDLVEDWE 
(creating a shared helix), as depicted in fig. S2, thereby deleting 
rNTSR1 residues V372–Y424. The software suite Rosetta was used 
to optimize the sequence of the shared helix and of possibly contacting 
residues. DARPin D12 was thus modified in its N-terminal region 
by deletion of residues S1 and D2 and by introduction of four point 
mutations, namely L3K, G4A, K5R, and A13K. Furthermore, the last 
two C-terminal D12 residues L157 and N158 were both mutated to 
alanine. Of note, the C-terminal region of the crystallized fusion 
construct, which includes a short linker sequence followed by a 
cleaved 3C protease site (see below), turned out to be partially 
a-helical and established crystal contacts. The receptor construct 
NTSR1- H4bmX is identical to NTSR1-H4X, with the exception that 
the receptor harbors the back-mutations D1242.61E, E1503.33D, 
V3587.42F, and A3627.46S, restoring the wild-type residues. For ex-
pression in Escherichia coli, the genes encoding the receptor con-
structs were cloned into a previously described pBR322-derived 
vector (35). Briefly, this resulted in an expression construct con-
sisting of an N-terminal maltose-binding protein (MBP), followed 
by a His6-tag, a human rhinovirus (HRV) 3C protease cleavage site 
(LEVLFQGP), a short linker (GS), the receptor itself fused to 
DARPin D12, a short linker (TRE), a second HRV 3C protease 
cleavage site, followed by thioredoxin A (TrxA), and a C-terminal 
His10-tag.
Expression and solubilization of NTSR1-H4X  
and NTSR1-H4bmX
NTSR1-H4X and NTSR1-H4bmX were expressed in E. coli BL21 
cells bearing a deletion of the fhuA2 gene to confer phage T1 resist-
ance (New England Biolabs). A starter culture of cells harboring the 
expression plasmid was grown overnight at 37°C in 2×YT medium 
containing 1% (w/v) glucose and ampicillin (100 mg/ml). One liter 
of expression cultures consisting of 2×YT, 0.2% (w/v) glucose, and 
ampicillin (100 mg/ml) was inoculated with the starter culture to an 
OD600 (optical density at 600 nm) of ~0.05 and grown at 37°C to an 
OD600 of ~0.5, followed by induction with 1 mM isopropyl-b-D- 
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Cells were harvested by centrifugation at 5000g for 20 min at 4°C, 
typically yielding ~7 g of pellet per 1 liter of culture. The cell pellet 
was resuspended with Resuspension Buffer [100 mM Hepes (pH 8.0), 
30% (v/v) glycerol, and 400 mM NaCl] at 4°C, frozen in liquid 
nitrogen, and stored at −80°C.
All the following steps were carried out at 4°C. Typically, 60 ml 
of frozen resuspended cells (corresponding to 20 g of pellet) was 
thawed and incubated with lysozyme (2 mg/ml) (Sigma-Aldrich), 5 mM 
MgCl2, and deoxyribonuclease (DNase) I (0.05 mg/ml) (Roche) for 
1 hour while stirring. For NTSR1-H4bmX, but not NTSR1-H4X, either 
NTS8–13 (AnaSpec) or SR48692 (Tocris) was added to a final con-
centration of 15 mM. Subsequently, receptors were solubilized by 
incubation with 2% (w/v) n-dodecyl-b-D-maltopyranoside (DDM; 
Anatrace) and 0.2% (w/v) cholesteryl hemisuccinate (CHS; Sigma- 
Aldrich) for 1 hour while stirring followed by sonication for 
30 min using a Sonifier 250 (Branson) at a duty cycle of 30% and 
output of 5.
Purification of NTSR1-H4X and NTSR1-H4bmX  
for LCP crystallization
All the following steps were carried out at 4°C. The lysate containing 
detergent-solubilized receptor was adjusted with imidazole (pH 8.0) 
to a final concentration of 20 mM and centrifuged at 20,000g for 
30 min. For NTSR1-H4bmX, but not NTSR1-H4X, all subsequent 
buffers were supplemented with 10 mM of either NTS8–13 or SR48692 
(final concentration). The supernatant was batch-incubated overnight 
with 20 ml of TALON Superflow resin (GE Healthcare) equilibrated 
with Wash Buffer I [25 mM Hepes (pH 8.0), 10% (v/v) glycerol, 600 mM 
NaCl, 0.1% (w/v) DDM, 5 mM MgCl2, 2 mM 2-mercaptoethanol 
(2-ME), and 20 mM imidazole (pH 8.0)]. Subsequently, the resin 
was washed with 10 column volumes (CVs) of Wash Buffer I fol-
lowed by 5 CVs of Wash Buffer II [25 mM Hepes (pH 8.0), 10% (v/v) 
glycerol, 150 mM NaCl, 0.1% (w/v) DDM, 2 mM 2-ME, and 20 mM 
imidazole (pH 8.0)]. Protein elution was carried out with 3 CVs of 
Elution Buffer [25 mM Hepes (pH 7.0), 10% (v/v) glycerol, 150 
mM NaCl, 0.1% (w/v) DDM, 2 mM 2-ME, and 250 mM imidazole 
(pH 8.0)]. The eluted protein was concentrated in two 100-kDa mo-
lecular weight cutoff Vivaspin 20 concentrators (Sartorius) to 2.5 ml 
each and subsequently desalted using two PD MiniTrap G-25 columns 
(GE Healthcare) equilibrated with G-25 Buffer [10 mM Hepes (pH 7.0), 
10% (v/v) glycerol, 0.05% (w/v) DDM, and 2 mM dithiothreitol 
(DTT)]. The protein was incubated for 3 hours with HRV 3C prote-
ase (produced in-house) to cleave off the fusion proteins MBP and 
TrxA. The mixture was loaded onto 2.5 ml of SP Sepharose cation 
exchange chromatography resin (GE Healthcare) equilibrated with 
G-25 Buffer. The resin was washed with 5 CVs of SP Wash Buffer I 
[10 mM Hepes (pH 7.7), 10% (v/v) glycerol, 35 mM NaCl, 0.025% (w/v) 
DDM, and 2 mM DTT] and with 5 CVs of SP Wash Buffer II 
[10 mM Hepes (pH 7.0), 10% (v/v) glycerol, 0.025% (w/v) DDM, 
0.005% (w/v) CHS, and 2 mM DTT] to remove the fusion proteins 
MBP and TrxA. Protein elution was carried out stepwise using 12 ml 
of SP Elution Buffer [10 mM Hepes (pH 7.0), 10% (v/v) glycerol, 
500 mM NaCl, 0.015% (w/v) DDM, 0.003% (w/v) CHS, and 2 mM 
DTT]. Fractions containing more than 0.6 mg/ml protein were 
combined and adjusted with SP Elution Buffer to 0.6 to 0.7 mg/ml 
in a typical final volume of 2.4 ml. Protein concentrations were de-
termined by absorbance at 280 nm using a NanoDrop 2000 spectro-
photometer (Thermo Fisher Scientific). Purified apo NTSR1-H4X 
was incubated overnight either without addition of any ligand or 
with 300 mM of either SRI-9829, RTI-3a (Tocris; commercial name, 
TC NTR1 17), SR48692 (Axon MedChem and Tocris), SR142948A 
(Axon MedChem), or NTS8–13 (AnaSpec and GenScript). Purified 
NTS8–13- or SR48692-bound NTSR1-H4bmX was incubated over-
night with 300 mM of the respective ligand. Subsequently, the protein 
sample was concentrated with a 100-kDa molecular weight cutoff 
Vivaspin 2 concentrator (Sartorius) to ~60 mg/ml, resulting in a 
typical final volume of 25 ml.
Purification of NTSR1-H4X for vapor  
diffusion crystallization
All the following steps were carried out at 4°C. NTSR1-H4X was pu-
rified from the lysate containing detergent-solubilized receptor via 
a pD-NT ligand affinity column followed by detergent exchange to 
nonyl-b-D-glucopyranoside (NG), 3C protease cleavage, and SP 
Sepharose cation exchange chromatography essentially as previously 
described (9, 35), with the exception that the final buffer exchange 
was carried out on a PD MiniTrap G-25 column (GE Healthcare) 
instead of by preparative gel filtration on a Superdex 200 10/300 GL 
column. The bound ligand consists of NTS8–13 with an additional 
four residues at its N terminus (GPGG), as it is cleaved off from the 
ligand affinity column.
Crystallization in LCP
Apo and ligand-bound NTSR1-H4X, as well as ligand-bound NTSR1- 
H4bmX, were reconstituted in LCP by mixing concentrated protein 
(~60 mg/ml) with molten monoolein (Sigma-Aldrich) supplemented 
with 10% (w/w) cholesterol (Sigma-Aldrich) at a protein-to-lipid 
ratio of 20:32 (v/v) using the two-syringe method (100-ml syringes; 
Hamilton). Crystallization trials were carried out at 20°C in 96-well 
glass sandwich plates (SWISSCI) with a 120-mm spacer. A Crystal 
Gryphon LCP crystallization robot (Art Robbins Instruments) was 
used to dispense 40-nl boli and to cover them with 800 nl of precip-
itant solution. The plates were immediately sealed with a cover glass 
and incubated at 20°C in Rock Imager 1000 (Formulatrix). All crystals 
obtained in this study were of rather small size, typically not exceed-
ing ~15 to 30 mm in any dimension. NTSR1-H4X, in complex with 
the ligands cocrystallized in this study, yielded crystals in a wide range 
of conditions in initial crystallization screens. Initial conditions were 
fine-screened and yielded optimized crystals used for data collection. 
Optimized crystallization conditions are summarized in table S12. 
Crystals were harvested by picking the entire bolus at room tem-
perature with 25-mm MicroMesh (MiTeGen) and flash-frozen in 
liquid nitrogen without adding further cryoprotectant.
Crystallization by vapor diffusion
Concentrated NTS8–13-bound NTSR1-H4X (~10 mg/ml) was adjusted 
to 0.6% (w/v) (final concentration) n-nonyl-b-D-glucoside (NG). 
Sitting drop crystallization trials were carried out at 4°C in 96-well 
Intelli-Plate 96-3 LVR plates (Art Robbins Instruments) containing 
75 ml of precipitant solution in each reservoir. A Crystal Gryphon 
crystallization robot (Art Robbins Instruments) was used to dis-
pense 0.5-ml drops of protein solution and to add 0.5 ml of precipi-
tant solution. The plates were immediately sealed with a plastic foil 
and incubated at 4°C in a Rock Imager 1000 (Formulatrix). Optimized 
crystals of NTS8–13-bound NTSR1-H4X used for data collection 
grew in a precipitant solution consisting of 50 mM glycine (pH 9.4), 
1 M NaCl, and 8.3% (w/v) PEG4000 (polyethylene glycol, molecular 
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and cryoprotected by incubation for ~10 s in a solution containing 
50 mM glycine (pH 9.4), 1 M NaCl, 0.3% (w/v) NG, 15% (v/v) 
PEG600, and 15% (v/v) glycerol. Cryoprotected crystals were flash- 
frozen in liquid nitrogen.
Data collection and structure determination
Collection of x-ray diffraction data was carried out at the X06SA 
(PXI) beamline at the Swiss Light Source of the Paul Scherrer Institute 
(Villigen, Switzerland). Mounted samples were kept in a cryostream 
at 100 K, and diffraction data were collected using a wavelength of 
1 Å and an EIGER 16M detector. Crystals embedded in LCP were 
located by diffraction using a grid scan protocol with a nonattenuated 
beam and an exposure time of 0.04 s. Data collection parameters 
were adjusted to optimize the signal-to-noise ratio. For crystals of 
NTSR1-H4X in complex with SRI-9829 and RTI-3a, diffraction data 
were recorded using the SSX suite (60). Partial datasets (minisets) 
were typically recorded using a 15 mm × 15 mm or 20 mm × 30 mm 
nonattenuated beam, an exposure time of 0.1 s, an oscillation angle 
of 0.2°, and an angular wedge of 10° to 20°. For crystals of NTSR1- 
H4bmX in complex with SR48692 and NTS8–13, partial datasets were 
recorded using a 15 mm × 15 mm beam attenuated to 50%, an expo-
sure time of 0.05 s, an oscillation angle of 0.2°, and an angular wedge 
of 20°. For crystals of NTSR1-H4X bound to NTS8–13 obtained by 
vapor diffusion crystallization, diffraction data were collected with 
a 30 mm × 30 mm attenuated beam, an exposure time of 0.05 s, a total 
angular range of 180°, and an oscillation angle of 0.1°. Datasets were 
obtained either from one or two large crystals (NTSR1-H4X bound 
to NTS8–13, SR48692, SR142948A, and for the apo form) or from a 
set of approximately 20 smaller LCP crystals that had similar cell 
parameters (NTSR1-H4X bound to SRI-9829 and RTI-3a, and NTSR1- 
H4bmX bound to NTS8–13 and SR48692). The data were indexed 
and integrated with XDS, while scaling was performed with AIMLESS 
within the CCP4 package. As all datasets of the several different crystal 
forms suffered from substantial anisotropic diffraction, data were 
anisotropy-corrected and merged using the STARANISO server (61) 
from Global Phasing Ltd. Starting with the best data, the structure 
of the NTSR1-H4X:NTS8–13 complex was determined by molecular 
replacement using PHASER, with the GPCR domain of 4XEE (10) 
as the search model. The top solution was then refined in multiple 
rounds of model building with COOT and refinement with BUSTER 
and REFMAC. Validation during the course of refinement was per-
formed using MolProbity within the PHENIX package. The coordi-
nates of chain A of the NTSR1-H4X:NTS8–13 complex were thereafter 
used to determine the structures of the apo form and the other com-
plexes using the same approach. Statistics for data collection and 
refinement of all structures can be found in tables S3 and S4.
Structural analysis
Receptors were structurally aligned using the command “align” in 
PyMOL and the 7TM bundle as template. To determine the RMSDCa 
value in the extracellular receptor half between NTS8–13-bound 
NTSR1-H4X and NTSR1-ELF (PDB ID: 4XEE) (10), only the resi-
dues in the extracellular half were aligned. Residues located above 
the conserved W3216.48 of the CWxP motif were considered to be-
long to the extracellular half, i.e., residues 51 to 72, 118 to 154, 197 
to 245, and 321 to 358, resulting in 146 Ca positions. Unless other-
wise stated, distances were generally measured between Ca atoms 
for backbone rearrangements, between ring centers for aromatic 
residues, and between polar atoms for polar interactions. Rearrange-
ments of the extracellular tips of TM6 and TM7 were determined 
between corresponding Ca atoms of residue 3336.60 for TM6 and 
residue 3427.26 for TM7. The receptor center is defined as the central 
axis of the 7TM bundle perpendicular to the membrane plane. 
Orthosteric ligand-binding cavity volumes were calculated with the 
program POVME 2.0 (62). As the cocrystallized ligands exhibited dis-
tinct extensions toward the extracellular receptor opening, an identical 
inclusion region obtained from the combined ligand dimensions 
from all structures was used to define the cavity boundaries.
Mammalian cell culture
Human embryonic kidney (HEK) 293T/17 cells and COS-7 cells 
(American Type Culture Collection) were cultivated in Dulbecco’s 
modified medium (Sigma-Aldrich) supplemented with penicillin 
(100 U/ml), streptomycin (100 mg/ml) (Sigma-Aldrich), and 10% (v/v) 
fetal calf serum (BioConcept). Cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. Transient transfec-
tions were performed with TransIT-293 (Mirus Bio) or Lipofectamine 
LTX (Thermo Fisher Scientific) for HEK293T/17 and COS-7 cells, 
respectively, according to the manufacturer’s instructions.
Ligand-binding assays
Ligand-binding experiments were performed on whole cells or on 
cell membranes obtained from transiently transfected HEK293T/17 
using a homogeneous time-resolved fluorescence (HTRF) binding 
assay. All receptor variants were cloned into a mammalian expres-
sion vector containing an N-terminal SNAP-tag (Cisbio), and point 
mutations were introduced by site-directed mutagenesis. The con-
structs NTSR1-H4X and NTSR1-H4X
DD12 are identical to the receptor 
construct used for crystallization, including a cleaved 3C protease 
site (GP) followed by a short linker (GS) at the N terminus and a 
short linker (TRE) followed by the cleaved 3C protease site (LEVLFQ) 
at the C terminus. In the construct NTSR1-H4X
DD12, DARPin D12 
was replaced by the wild-type rNTSR1 sequence V372–G390. 
HEK293T/17 cells were transiently transfected with receptor con-
structs and were seeded at 20,000 cells per well in poly-L-lysine–
coated 384-well plates (Greiner) for whole-cell binding assays or at 
5 × 106 cells in 10-cm petri dishes for membrane preparation. 
Forty-eight hours after transfection, cells were labeled with 50 nM 
SNAP-Lumi4-Tb (Cisbio) in assay buffer [20 mM Hepes (pH 7.5), 
100 mM NaCl, 3 mM MgCl2, and 0.2% (w/v) nonfat milk] for 
1.5 hours at 37°C. Thereafter, cells were washed four times with as-
say buffer and used directly for whole-cell ligand-binding experi-
ments, or crude cell membrane extracts were prepared as described 
before (63). Cells or 0.2- to 1-mg membranes per well were then in-
cubated for 4 hours at room temperature in assay buffer containing 
fluorescently labeled peptide HL488-NTS8–13 (NTS8–13 labeled with 
HiLyte Fluor 488 at the N terminus) (Eurogentec). For competition 
binding, 0.5 to 100 nM HL488-NTS8–13 tracer peptide and concen-
tration ranges of unlabeled competitor ligands were used. Fluores-
cence intensities were measured on an Infinite M1000 fluorescence 
plate reader (Tecan) with an excitation wavelength of 340 nm and 
emission wavelengths of 620 and 520 nm for Tb3+ and fluorophore 
HiLyte Fluor 488, respectively. The ratio of FRET (fluorescence res-
onance energy transfer) donor and acceptor fluorescence intensities 
(F520/F620 nm) was calculated. Total binding was obtained in the 
absence of competitor, and nonspecific binding was determined in 
the presence of 100 mM unlabeled NTS8–13. Data were normalized to 
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by global fitting to a one-site heterologous competition equation with 
the GraphPad Prism software (version 6.07). To obtain Ki values, 
data were corrected for fluorescent ligand occupancy of each mutant 
with the Cheng-Prusoff equation (64).
Signaling assays
All signaling assays were performed with receptor constructs har-
boring the full-length C terminus. Ligand-induced IP1 (a metabolite of 
IP3) accumulation was measured in transiently transfected HEK293T/17 
cells, as described before (65). Basal receptor activity was measured 
in COS-7 cells transiently transfected with Gaq and the respective 
receptor construct. Twenty-four hours after transfection, cells were 
washed with phosphate-buffered saline (PBS), detached with trypsin- 
EDTA, and resuspended in assay buffer [10 mM Hepes (pH 7.4), 1 mM 
CaCl2, 0.5 mM MgCl2, 4.2 mM KCl, 146 mM NaCl, 50 mM LiCl, 
5.5 mM glucose, and 0.2% (w/v) bovine serum albumin (BSA)]. 
Cells were seeded at 20,000 cells per well in white 384-well plates 
(Greiner) and incubated for 2 hours at 37°C with a concentration 
range of ligands diluted in assay buffer. For basal receptor activity, 
cells were resuspended in assay buffer devoid of LiCl and ligand. 
Basal IP1 accumulation was then initiated by adding 50 mM LiCl 
for the indicated time intervals. IP1 accumulation was determined 
using the HTRF IP-One Kit (Cisbio) according to the manufac-
turer’s protocol. Fluorescence intensities were measured on an 
Infinite M1000 fluorescence plate reader (Tecan). To generate 
concentration-response curves, data were analyzed by a three- 
parameter logistic equation in GraphPad Prism software (version 
6.07). For time-dependent basal IP1 generation, data were normalized 
to IP1 concentrations obtained from stimulation of the respective 
receptor construct with 10 mM NTS8–13 for 120 min and analyzed by 
linear regression.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/5/eabe5504/DC1
View/request a protocol for this paper from Bio-protocol.
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